CNBC Reports Strong Phase 3 Results for Eli Lilly’s Retatrutide Eli Lilly's experimental obesity drug, retatrutide, has made significant strides in its Phase 3 clinical trial, showing promising results for patients without diabetes.
The trial's success has garnered interest from investors and medical professionals alike, with many hailing it as a potential game changer in the treatment of obesity.
A New Generation of Obesity Treatment Retatrutide's unique mechanism of action sets it apart from current weight loss medications like Wegovy and Zepbound.